SH2D1A and hemophagocytic syndrome: Such patients may have a SAP replete population as low as 5–8%, which leads to significantly prolonged survival without transplant (up to 40 years reported) suggesting a significant reduction in the risk of developing HLH and possibly malignancy, even with low levels of corrected cells (Palendira et al., 2012; Hoshino et al., 2018).